Assessing quality-of-life outcomes in cardiovascular clinical research

Nature Reviews Cardiology

Volumn 13, Issue 5, 2016, Pages 286-308

  Mark, Daniel B ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABLATION THERAPY; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL DECISION MAKING; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DEVICE THERAPY; HEALTH CARE COST; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANSCATHETER AORTIC VALVE IMPLANTATION; CARDIOVASCULAR DISEASES; HEALTH STATUS; PREDICTIVE VALUE; PSYCHOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; REPRODUCIBILITY; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; HEALTH STATUS; HUMANS; PREDICTIVE VALUE OF TESTS; PSYCHOMETRICS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84958787243     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2016.10     Document Type: Review

References (175)

1. Bakas, T., et al. Systematic review of health-related quality of life models. Health Qual. Life Outcomes 10, 134 (2012
2. Bergner, M. Quality of life, health status, and clinical research. Med. Care 27, S148-S156 (1989
3. Armstrong, D., & Caldwell, D. Origins of the concept of quality of life in health care: a rhetorical solution to a political problem. Soc. Theory Health 2, 361-371 (2004
4. Reiser, S. J. Medicine and the Reign of Technology (Cambridge Univ. Press, 1981
5. Gruenberg, E. M. The failures of success. Milbank Mem. Fund. Q. Health Soc. 55, 3-24 (1977
6. Cluff, L. E. Chronic disease, function and the quality of care. J. Chron. Dis. 34, 299-304 (1981
7. McDermott, W. Absence of indicators of the influence of its physicians on a society's health; impact of physician care on society. Am. J. Med. 70, 833-843 (1981
8. Tarlov, A. R. Shattuck lecture-The increasing supply of physicians, the changing structure of the health-services system, and the future practice of medicine. N. Engl. J. Med. 308, 1235-1244 (1983
9. Johnson, J. R., & Temple, R. Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat. Rep. 69, 1155-1159 (1985
10. Croog, S. H., et al. The effects of antihypertensive therapy on the quality of life. N. Engl. J. Med. 314, 1657-1664 (1986
11. Bruce, R. A. Evaluation of functional capacity and exercise tolerance of cardiac patients. Mod. Concepts Cardiovasc. Dis. 25, 321-326 (1956
12. Geigle, R., & Jones, S. B. Outcomes measurement: a report from the front. Inquiry 27, 7-13 (1990
13. Rahimi, K., Malhotra, A., Banning, A. P., & Jenkinson, C. Outcome selection and role of patient reported outcomes in contemporary cardiovascular trials: systematic review. BMJ 341, c5707 (2010
14. Goldfarb, M., et al. Outcome reporting in cardiac surgery trials: systematic review and critical appraisal. J. Am. Heart Assoc. 4, e002204 (2015
15. McDowell, I. Measuring Health: A Guide to Rating Scales and Questionnaires (Oxford Univ. Press, 2006
16. Jones, L. V., & Thissen, D. A. in Handbook of Statistics Vol. 26. (eds Rao, C. R., & Sinharay, S.) 1-27 (Elsevier, 2006
17. Spector, P. E. Summated Rating Scales Construction: An Introduction (SAGE Publications, 1992
18. DeVellis, R. F. Scale Development: Theory and Applications (Applied Social Research Methods) 3rd edn (SAGE Publications, 2012
19. Fayers, P. M. Quality-of life measurement in clinical trials-The impact of causal variables. J. Biopharm. Stat. 14, 155-176 (2004
20. Williams, J. I., & Naylor, C. D. How should health status measures be assessed? Cautionary notes on procrustean frameworks. J. Clin. Epidemiol. 45, 1347-1351 (1992
21. Costa, D. S., & King, M. T. Conceptual, classification or causal: models of health status and health-related quality of life. Expert Rev. Pharmacoecon. Outcomes Res. 13, 631-640 (2013
22. Wilson, I. B., & Cleary, P. D. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 273, 59-65 (1995
23. Ferrans, C. E., Zerwic, J. J., Wilbur, J. E., & Larson, J. L. Conceptual model of health-related quality of life. J. Nurs. Scholarsh.37, 336-342 (2005
24. Cassel, E. J. The nature of suffering and the goals of medicine. N. Engl. J. Med. 306, 639-645 (1982
25. Stewart, A. L., & Ware, J. E. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach (Duke Univ. Press Books, 1992
26. Fairclough, D. L. Design and Analysis of Quality of Life Studies in Clinical Trials 2nd edn (Chapman and Hall/CRC, 2010
27. Cleary, P. D. in Quality of Life and Pharmacoeconomics in Clinical Trials (ed. Spilker, B.) 73-78 (Lippencott Williams & Wilkins, 1996
28. Wiebe, S., Guyatt, G., Weaver, B., Matijevic, S., & Sidwell, C. Comparative responsiveness of generic and specific quality-of life instruments. J. Clin. Epidemiol. 56, 52-60 (2003
29. Scoggins, J. F., & Patrick, D. L. The use of patient-reported outcomes instruments in registered clinical trials: evidence from ClinicalTrials.gov. Contemp. Clin. Trials 30, 289-292 (2009
30. Testa, M. A., Anderson, R. B., Nackley, J. F., & Hollenberg, N. K. Quality of life and antihypertensive therapy in men-A comparison of captopril with enalapril. N. Engl. J. Med. 328, 907-913 (1993
31. Department of Health & Human Services, U. S. PROMIS®: dynamic tools to measure health outcomes from the patient perspective [online], http://www.nihpromis.org (2016
32. Ara, R., & Wailoo, A. Using health state utility values in models exploring the cost-effectiveness of health technologies. Value Health 15, 971-974 (2012
33. Knapp, T R the Reliability of Measuring Instruments (Edgeworth Laboratory, 2002
34. Furr, R. M., & Bacharach, V. R. Psychometrics: An Introduction (SAGE Publications, 2013
35. U.S. Department of Health and Human Services. Patient-reported outcome measures: use in medical product development to support labeling claims. U.S Food and Drug Administration [online], http://www.fda.gov/downloads/Drugs//Guidances/UCM193282.pdf (2009
36. Guyatt, G. H., Feeny, D. H., & Patrick, D. L. Measuring health-related quality of life. Ann. Intern. Med. 118, 622-629 (1993
37. Revicki, D., Hays, R. D., Cella, D., & Sloan, J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J. Clin. Epidemiol. 61, 102-109 (2008
38. Liang, M. H. Longitudinal construct validity: establishment of clinical meaning in patient evaluative instruments. Med. Care 38 (9 Suppl.), II84-II90 (2000
39. Cook, T D., & DeMets, D. L. Introduction to Statistical Methods for Clinical Trials (CRC Press, 2008
40. Rubin, D. B. Causal inference through potential outcomes and principal stratification: application to studies with 'censoring' due to death. Statist. Sci. 21, 299-309 (2006
41. Mark, D. B., et al. Quality-of life outcomes with coronary artery bypass graft surgery in ischemic left ventricular dysfunction: a randomized trial. Ann. Intern. Med. 161, 392-399 (2014
42. Hayden, D., Pauler, D. K., & Schoenfeld, D. An estimator for treatment comparisons among survivors in randomized trials. Biometrics 61, 305-310 (2005
43. Ware, J. E. Measuring patients' views: the optimum outcome measure. BMJ 306, 1429-1430 (1993
44. McGlothlin, A. E., & Lewis, R. J. Minimal clinically important difference: defining what really matters to patients. JAMA 312, 1342-1343 (2014
45. Crosby, R. D., Kolotkin, R. L., & Williams, G. R. Defining clinically meaningful change in health-related quality of life. J. Clin. Epidemiol. 56, 395-407 (2003
46. Streiner, D. L., & Norman, G. R. Health Measurement Scales: A Practical Guide To Their Development And Use (Oxford Univ. Press, 2008
47. Wright, A., Hannon, J., Hegedus, E. J., & Kavchak, A. E. Clinimetrics corner: a closer look at the minimal clinically important difference (MCID). J. Man. Manip. Ther. 20, 160-166 (2012
48. Fayers, P. M., & Manchin, D. Quality of Life: The Assessment, Analysis and Interpretation of Patient-reported Outcomes 2nd edn (Wiley-Blackwell, 2007
49. Brettschneider, C., et al. Relative impact of multimorbid chronic conditions on health-related quality of life-results from the MultiCare Cohort Study. PLoS ONE 8, e66742 (2013
50. Rapkin, B. D., & Schwartz, C. E. Toward a theoretical model of quality-of life appraisal: implications of findings from studies of response shift. Health Qual. Life Outcomes 2, 14 (2004
51. Ubel, P. A., Peeters, Y., & Smith, D. Abandoning the language of 'response shift': a plea for conceptual clarity in distinguishing scale recalibration from true changes in quality of life. Qual. Life Res. 19, 465-471 (2010
52. Sprangers, M. A., & Schwartz, C. E. Do not throw out the baby with the bath water: build on current approaches to realize conceptual clarity. Response to Ubel, Peeters, and Smith. Qual. Life Res. 19, 477-479 (2010
53. Feinstein, A. R. Clinimetrics (Yale Univ. Press, 1987
54. Fava, G. A., & Belaise, C. A discussion on the role of clinimetrics and the misleading effects of psychometric theory. J. Clin. Epidemiol. 58, 753-756 (2005
55. Streiner, D. L. Clinimetrics versus psychometrics: an unnecessary distinction. J. Clin. Epidemiol. 56, 1142-1145 (2003
56. Calman, K. C. Quality of life in cancer patients-An hypothesis. J. Med. Ethics 10, 124-127 (1984
57. Ruta, D. A., Garratt, A. M., Leng, M., Russell, I. T., & MacDonald, L. M. A new approach to the measurement of quality of life. The Patient-Generated Index. Med. Care 32, 1109-1126 (1994
58. Ruta, D. A., Garratt, A. M., & Russell, I. T. Patient centred assessment of quality of life for patients with four common conditions. Qual. Health Care 8, 22-29 (1999
59. Joyce, C. R., Hickey, A., McGee, H. M., & O'Boyle, C. A. A theory-based method for the evaluation of individual quality of life: the SEIQoL. Qual. Life Res. 12, 275-280 (2003
60. European Medicines Agency Committee for Medicinal Products for Human Use. Reflection paper on the regulatory guidance for the use of health related quality of life (HRQL) measures in the evaluation of medicinal products. International Society for Pharmacoeconomics and Outcomes Research [online], http://www.ispor.org/workpaper/emea-hrql-guidance.pdf (2005
61. Revicki, D. A. FDA draft guidance and health-outcomes research. Lancet 369, 540-542 (2007
62. Gnanasakthy, A., et al. A review of patient-reported outcome labels in the United States: 2006 to 2010. Value Health 15, 437-442 (2012
63. DeMuro, C., et al. Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and biologic license applications, 2006-2010. Value Health 15, 443-448 (2012
64. DeMuro, C., et al Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010). 16, 1150-1155 (2013
65. Neill, W. A., et al. Cardiac disability. The impact of coronary heart disease on patients' daily activities. Arch. Intern. Med. 145, 1642-1647 (1985
66. Skinner, J. S., Albers, C. J., Hall, R. J., & Adams, P. C. Comparison of Nottingham Health Profile (NHP) scores with exercise duration and measures of ischaemia during treadmill exercise testing in patients with coronary artery disease. Eur. Heart J. 16, 1561-1565 (1995
67. Ades, P. A., et al. Determinants of disability in older coronary patients. Am. Heart J. 143, 151-156 (2002
68. Spertus, J. A., McDonell, M., Woodman, C. L., & Fihn, S. D. Association between depression and worse disease-specific functional status in outpatients with coronary artery disease. Am. Heart J. 140, 105-110 (2000
69. Spertus, J. A., et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J. Am. Coll. Cardiol. 25, 333-341 (1995
70. Chan, P. S., Jones, P. G., Arnold, S. A., & Spertus, J. A. Development and validation of a short version of the Seattle Angina Questionnaire. Circ. Cardiovasc. Qual. Outcomes 7, 640-647 (2014
71. Hofer, S., Lim, L., Guyatt, G., & Oldridge, N. The MacNew Heart Disease health-related quality of life instrument: a summary. Health Qual. Life Outcomes 2, 3 (2004
72. Hlatky, M. A., et al. A brief self-Administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am. J. Cardiol. 64, 651-654 (1989
73. Hlatky, M. A., et al. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. N. Engl. J. Med. 336, 92-99 (1997
74. Boden, W. E., et al. Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med. 356, 1503-1516 (2007
75. Weintraub, W. S., et al. Effect of PCI on quality of life in patients with stable coronary disease. N. Engl. J. Med. 359, 677-687 (2008
76. Serruys, P. W., et al. Percutaneous coronary intervention versus coronary-Artery bypass grafting for severe coronary artery disease. N. Engl. J. Med. 360, 961-972 (2009
77. Cohen, D. J., et al. Quality of life after PCI with drug-eluting stents or coronary-Artery bypass surgery. N. Engl. J. Med. 364, 1016-1026 (2011
78. Farkouh, M. E., et al. Strategies for multivessel revascularization in patients with diabetes. N. Engl. J. Med. 367, 2375-2384 (2012
79. Abdallah, M. S., et al. Quality of life after PCI versus CABG among patients with diabetes and multivessel coronary artery disease: a randomized clinical trial. JAMA 310, 1581-1590 (2013
80. Nieminen, M. S., et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur. Heart J. 26, 384-416 (2005
81. Gheorghiade, M., et al. Acute heart failure syndromes: current state and framework for future research. Circulation 112, 3958-3968 (2005
82. West, R. L., Hernandez, A. F., O'Connor, C. M., Starling, R. C., & Califf, R. M. A review of dyspnea in acute heart failure syndromes. Am. Heart J. 160, 209-214 (2010
83. Sauser, K., Spertus, J. A., Pierchala, L., Davis, E., & Pang, P. S. Quality of life assessment for acute heart failure patients from emergency department presentation through 30 days after discharge: a pilot study with the Kansas City Cardiomyopathy Questionnaire. J. Card. Fail. 20, 18-22 (2014
84. Pang, P. S., et al. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur. Heart J. 29, 816-824 (2008
85. AbouEzzeddine, O. F., et al. Evaluation of a provocative dyspnea severity score. Am. Heart J. 172, 34-41 (2016
86. Allen, L. A., et al. Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF). J. Card. Fail. 14, 777-784 (2008
87. Publication Committee for the VMAC Investigators. Intravenous nesiritide versus nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287, 1531-1540 (2002
88. O'Connor, C. M., et al. Effect of nesiritide in patients with acute decompensated heart failure. N. Engl. J. Med. 365, 32-43 (2011
89. Wilson, J. R., Rayos, G., Yeoh, T. K., Gothard, P., & Bak, K. Dissociation between exertional symptoms and circulatory function in patients with heart failure. Circulation 92, 47-53 (1995
90. Piepoli, M. F., et al. Exercise intolerance in chronic heart failure: mechanisms and therapies. Part I. Eur. J. Cardiovasc. Prev. Rehabil. 17, 637-642 (2010
91. Witte, K. K., & Clark, A. L. Why does chronic heart failure cause breathlessness and fatigue? Prog. Cardiovasc. Dis. 49, 366-384 (2007
92. Wilson, J. R., Hanamanthu, S., Chomsky, D. B., & Davis, S. F. Relationship between exertional symptoms and functional capacity in patients with heart failure. J. Am. Coll. Cardiol. 33, 1943-1947 (1999
93. Russell, S. D., McNeer, F. R., & Higginbotham, M. B. Exertional dyspnea in heart failure: a symptom unrelated to pulmonary function at rest or during exercise. Am. Heart J. 135, 398-405 (1998
94. Clark, A. L. Origin of symptoms in chronic heart failure. Heart 92, 12-16 (2006
95. Coats, A. J., Clark, A. L., Piepoli, M., Volterrani, M., & Poole-Wilson, P. A. Symptoms and quality of life in heart failure: the muscle hypothesis. Br. Heart J. 72, S36-S39 (1994
96. Goldman, L., et al. Pitfalls in the serial assessment of cardiac functional status. How a reduction in 'ordinary' activity may reduce the apparent degree of cardiac compromise and give a misleading impression of improvement. J. Chronic Dis. 35, 763-771 (1982
97. Rumsfeld, J. S., et al. Depressive symptoms are the strongest predictors of short-Term declines in health status in patients with heart failure. J. Am. Coll. Cardiol. 42, 1811-1187 (2003
98. Havranek, E. P., Spertus, J. A., Masoudi, F. A., Jones, P. G., & Rumsfeld, J. S. Predictors of the onset of depressive symptoms in patients with heart failure. J. Am. Coll. Cardiol. 44, 2333-2338 (2004
99. Rector, T. S., Francis, G. S., & Cohn, J. N. Patients' self assessment of their congestive heart failure. Part 1: Patient perceived dysfunction and its poor correlation with maximal exercise tests. Heart Fail. 3, 192-196 (1987
100. Rector, T. S., Kubo, S. H., & Cohn, J. N. Patients' self-Assessment of their congestive heart failure. Part 2: Content, reliability, and validity of a new measure, the Minnesota Living with Heart Failure questionnaire. Heart Fail. 3, 198-209 (1987
101. Rector, T. S., et al. Use of the Living With Heart Failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death. J. Card. Fail. 1, 201-206 (1995
102. Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J. Am. Coll. Cardiol. 35, 1245-1255 (2000
103. Spertus, J., et al. Monitoring clinical changes in patients with heart failure: a comparison of methods. Am. Heart J. 150, 707-715 (2005
104. Spertus, J. A., & Jones, P. G. Development and validation of a short version of the Kansas City Cardiomyopathy Questionnaire. Circ. Cardiovasc. Qual. Outcomes 8, 469-476 (2015
105. Rogers, W. J., et al. Quality of life among 5, 025 patients with left ventricular dysfunction randomized between placebo and enalapril: the studies of left ventricular dysfunction. J. Am. Coll. Cardiol. 23, 393-400 (1994
106. Rector, T. S., Kubo, S. H., & Cohn, J. N. Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am. J. Cardiol. 71, 1106-1107 (1993
107. Taylor, A. L., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med. 351, 2049-2057 (2004
108. Hjalmarson, A., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT HF). JAMA 283, 1295-1302 (2000
109. Tate, C. W. 3rd, et al. Quality of life and prognosis in heart failure: results of the Beta-Blocker Evaluation of Survival Trial (BEST). J. Card. Fail. 13, 732-737 (2007
110. Gallanagh, S., et al. Evaluation of the functional status questionnaire in heart failure: a sub-study of the second cardiac insufficiency bisoprolol survival study (CIBIS II). Cardiovasc. Drugs Ther. 25, 77-85 (2011
111. Cohn, J. N., et al. Safety and efficacy of carvedilol in severe heart failure. J. Card. Fail. 3, 173-179 (1997
112. Cleland, J. G., et al. A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the 'patient journey') in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET). J. Am. Coll. Cardiol. 47, 1603-1611 (2006
113. Gelber, R. D., & Gelber, S. Quality-of life assessment in clinical trials. Cancer Treat. Res. 75, 225-246 (1995
114. Velazquez, E. J., et al. Coronary-Artery bypass surgery in patients with left ventricular dysfunction. N. Engl. J. Med. 364, 1607-1616 (2011
115. Abraham, W. T., et al. Cardiac resynchronization in chronic heart failure. N. Engl. J. Med. 346, 1845-1853 (2002
116. Cleland, J. G., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med. 352, 1539-1549 (2005
117. Cleland, J. G., Calvert, M. J., Verboven, Y., & Freemantle, N. Effects of cardiac resynchronization therapy on long-Term quality of life: an analysis from the CArdiac Resynchronisation-Heart Failure (CARE HF) study. Am. Heart J. 157, 457-466 (2009
118. De Marco, T., et al. Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-study. J. Card. Fail. 14, 9-18 (2008
119. Veazie, P. J., et al. Cardiac resynchronization and quality of life in patients with minimally symptomatic heart failure. J. Am. Coll. Cardiol. 60, 1940-1944 (2012
120. Rose, E. A., et al. Long-Term use of a left ventricular assist device for end-stage heart failure. N. Engl. J. Med. 345, 1435-1443 (2001
121. Slaughter, M. S., et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N. Engl. J. Med. 361, 2241-2251 (2009
122. Kim, C. A., et al. Functional status and quality of life after transcatheter aortic valve replacement: a systematic review. Ann. Intern. Med. 160, 243-254 (2014
123. Leon, M. B., et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N. Engl. J. Med. 363, 1597-1607 (2010
124. Reynolds, M. R., et al. Health-related quality of life after transcatheter aortic valve replacement in inoperable patients with severe aortic stenosis. Circulation 124, 1964-1972 (2011
125. Reynolds, M. R., et al. Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results from the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial (Cohort A). J. Am. Coll. Cardiol. 60, 548-558 (2012
126. Arnold, S. V., et al. How to define a poor outcome after transcatheter aortic valve replacement: conceptual framework and empirical observations from the placement of aortic transcatheter valve (PARTNER) trial. Circ. Cardiovasc. Qual. Outcomes 6, 591-597 (2013
127. Gronefeld, G. C., & Hohnloser, S. H. Quality of life in atrial fibrillation: an increasingly important issue. Eur. Heart J. 5, H25-H33 (2003
128. Rienstra, M., et al. Symptoms and functional status of patients with atrial fibrillation: state of the art and future research opportunities. Circulation 125, 2933-2943 (2012
129. Savelieva, I., Paquette, M., Dorian, P., Luderitz, B., & Camm, A. J. Quality of life in patients with silent atrial fibrillation. Heart 85, 216-217 (2001
130. Aliot, E., Botto, G L., Crijns, H. J., & Kirchhof, P. Quality of life in patients with atrial fibrillation: how to assess it and how to improve it. Europace 16, 787-796 (2014
131. Bubien, R. S., Knotts-Dolson, S. M., Plumb, V. J., & Kay, G. N. Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias. Circulation 94, 1585-1591 (1996
132. Reynolds, M. R., Ellis, E., & Zimetbaum, P. Quality of life in atrial fibrillation: measurement tools and impact of interventions. J. Cardiovasc. Electrophysiol. 19, 762-768 (2008
133. Wokhlu, A., et al. Long-Term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect. J. Am. Coll. Cardiol. 55, 2308-2316 (2010
134. US National Library of Science. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00911508 (2015
135. Arribas, F., et al. Validation of the AF QoL, a disease-specific quality of life questionnaire for patients with atrial fibrillation. Europace 12, 364-370 (2010
136. Mont, L., et al. Catheter ablation versus antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). Eur. Heart J. 35, 501-507 (2014
137. Spertus, J., et al. Development and validation of the Atrial Fibrillation Effect on QualiTy-of Life (AFEQT) Questionnaire in patients with atrial fibrillation. Circ. Arrhythm. Electrophysiol. 4, 15-25 (2011
138. Freeman, J. V., et al. Association between atrial fibrillation symptoms, quality of life, and patient outcomes: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT AF). Circ. Cardiovasc. Qual. Outcomes 8, 393-402 (2015
139. Jenkins, L. S., et al. Quality of life in atrial fibrillation: the Atrial Fibrillation Follow up Investigation of Rhythm Management (AFFIRM) study. Am. Heart J. 149, 112-120 (2005
140. Hagens, V. E., et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J. Am. Coll. Cardiol. 43, 241-247 (2004
141. Suman-Horduna, I., et al. Quality of life and functional capacity in patients with atrial fibrillation and congestive heart failure. J. Am. Coll. Cardiol. 61, 455-460 (2013
142. Wilber, D. J., et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 303, 333-340 (2010
143. Reynolds, M. R., Walczak, J., White, S. A., Cohen, D. J., & Wilber, D. J. Improvements in symptoms and quality of life in patients with paroxysmal atrial fibrillation treated with radiofrequency catheter ablation versus antiarrhythmic drugs. Circ. Cardiovasc. Qual. Outcomes 3, 615-623 (2010
144. Cosedis Nielsen, J., et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N. Engl. J. Med. 367, 1587-1595 (2012
145. Morillo, C. A., et al. Radiofrequency ablation versus antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT 2): a randomized trial. JAMA 311, 692-700 (2014
146. Pappone, C., et al. Radiofrequency catheter ablation and antiarrhythmic drug therapy: a prospective, randomized, 4 year follow up trial: the APAF study. Circ. Arrhythm. Electrophysiol. 4, 808-814 (2011
147. Riis, J., et al. Ignorance of hedonic adaptation to hemodialysis: a study using ecological momentary assessment. J. Exp. Psychol. Gen. 134, 3-9 (2005
148. World Health Organization. Consitution of the World Health Organization. Am. J. Public Health Nations Health 36, 1315-1323 (1946
149. Brook, R. H., et al. Does free care improve adults' health? Results from a randomized controlled trial. N. Engl. J. Med. 309, 1426-1434 (1983
150. Bergner, M., Bobbitt, R. A., Carter, W. B., & Gilson, B. S. The Sickness Impact Profile: development and final revision of a health status measure. Med. Care 19, 787-805 (1981
151. Bergner, M., et al. The Sickness Impact Profile: conceptual formulation and methodology for the development of a health status measure. Int. J. Health Serv. 6, 393-415 (1976
152. Kaplan, R. M., Bush, J. W., & Berry, C. C. Health status: types of validity and the index of well-being. Health Serv. Res. 11, 478-507 (1976
153. Torrance, G. W. Toward a utility theory foundation for health status index models. Health Serv. Res. 11, 349-369 (1976
154. Patrick, D. L., & Erickson, P. Health Status and Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation (Oxford Univ. Press, 1993
155. Califf, R M., Mark, D. B., & Wagner, G. S. Acute Coronary Care In The Thrombolytic Era 2nd edn (Mosby, 1995
156. Douglas, P. S., et al. PROspective Multicenter Imaging Study for Evaluation of chest pain: rationale and design of the PROMISE trial. Am. Heart J. 167, 796-803.e1 (2014
157. US National Library of Science. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01471522 (2015
158. Califf, R. M., et al. One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO I) trial. Circulation 94, 1233-1238 (1996
159. Mark, D. B., et al. Quality of life after late invasive therapy for occluded arteries. N. Engl. J. Med. 360, 774-783 (2009
160. Hlatky, M. A., et al. The effect of obesity on quality of life in patients with diabetes and coronary artery disease. Am. Heart J. 159, 292-300 (2010
161. Arnold, S. V., et al. Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial. Circ. Cardiovasc. Qual. Outcomes 1, 107-115 (2008
162. Majani, G., et al. Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial. J. Card. Fail. 11, 253-259 (2005
163. Wong, C. M., et al. Clinical characteristics and outcomes of young and very young adults with heart failure: the CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). J. Am. Coll. Cardiol. 62, 1845-1854 (2013
164. Park, S. J., et al. Left ventricular assist devices as destination therapy: a new look at survival. J. Thorac. Cardiovasc. Surg. 129, 9-17 (2005
165. Aranda, J. M. Jr, Conti, J. B., Johnson, J. W., Petersen Stejskal, S., & Curtis, A. B. Cardiac resynchronization therapy in patients with heart failure and conduction abnormalities other than left bundle-branch block: analysis of the Multicenter InSync Randomized Clinical Evaluation (MIRACLE). Clin. Cardiol. 27, 678-682 (2004
166. Flynn, K. E., et al. Effects of exercise training on health status in patients with chronic heart failure: HF ACTION randomized controlled trial. JAMA 301, 1451-1459 (2009
167. Mark, D. B., et al. Quality of life and economic outcomes with surgical ventricular reconstruction in ischemic heart failure: results from the Surgical Treatment for Ischemic Heart Failure trial. Am. Heart J. 157, 837-844 (2009
168. McMurray, J. J., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371, 993-1004 (2014
169. Hamo, C. E., et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circ. Heart Fail. 8, 268-277 (2015
170. Xiong, G. L., et al. Health status and depression remission in patients with chronic heart failure: patient reported outcomes from the SADHART-CHF trial. Circ. Heart Fail. 5, 688-692 (2012
171. Califf, R. M., et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am. Heart J. 134, 44-54 (1997
172. Dorian, P., et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J. Am. Coll. Cardiol. 36, 1303-1309 (2000
173. Singh, S. N., et al. Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy. J. Am. Coll. Cardiol. 48, 721-730 (2006
174. Kay, G. N., et al. The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators. J. Interv. Card. Electrophysiol. 2, 121-135 (1998
175. Groenveld, H. F., et al. The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J. Am. Coll. Cardiol. 58, 1795-1803 (2011